Tumour lysis syndrome (Q40165): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
Grupo de complicações metabólicas que podem ocorrer após o tratamento do câncer, geralmente linfomas e leucemias, e às vezes até mesmo sem tratamento. Essas complicações são causadas pelos produtos de degradação das células cancerosas mortas e incluem hipercalemia, hiperfosfatemia, hiperuricemia e hiperuricosúria, hipocalcemia e consequente nefropatia aguda por ácido úrico e insuficiência renal aguda.
description / endescription / en
 
This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.

Revision as of 05:52, 13 August 2026

This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.
Language Label Description Also known as
default for all languages
5D01
    English
    Tumour lysis syndrome
    This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.

      Statements